Heparinol

Heparin Na

Treatment & prevention of blood clots in blood vessels, arteries or lungs; used before surgery to reduce risk of blood clotting; hematological exam in laboratory; to stop dangerous blood clots that may form in the hemodialysis machines.

Individually titrate to desired effect (1.5-2.5 times control clotting used). Venous thrombosis or pulmonary embolus Continuous IV soln Initially 50-100 u/kg then 10-15 u/kg/hr (venous thrombosis) or 20 u/kg/hr (pulmonary embolus). Intermittent IV 75-125 u/kg 4 hrly. IV loading dose: 5,000 u followed by 10,000-20,000 u SC then 8,000-10,000 u 8 hrly or 15,000-20,000 u 12 hrly. Prophylaxis of DVT SC (low dose) 5,000 u 2 hr pre-op repeated every 8-12 hr until patient is ambulatory. Heparin lock flush IV Inject sufficient soln (10-100 u/mL) into inj hub to fill the entire heparin lock after each use. Hemodialysis 7,500-12,500 IU (w/o preservative) per dialysis. MI 5,000 IU SC 12 hrly beginning during the 12 hr after the first sign of MI. IV 5,00-10,000 IU 4 hrly by bolus inj or continuous infusion in NaCl or dextrose inj. SC 10,000 IU 8 hrly after initial IV bolus inj of 5,000 IU. Low dose heaparin Patient >40 yr undergoing abdominal or thoracic surgery 5,000 IU SC 2 hr pre-op then 5,000 IU SC 8-12 hrly w/o lab control for 7 days.

Hypersensitivity. Patients w/ uncontrolled active bleeding stage, thrombocytopenia, jaundice. Not to be used in the presence of actual or potential haemorrhagic stages eg, haemophilia, ascorbic acid deficiency or increased capillary fragility, threatened abortion, immediate postpartum period, subacute bacterial endocarditis, severe HTN, suspected intracranial haemorrhage, gastric or duodenal ulcers, after eye, brain or spinal cord surgery. Advanced renal or hepatic disease.

History of allergy to animal tissue (bovine mucous). Monitor carefully to reduce risk of overdosage, haemorrhage & serious adverse reactions eg, delayed onset thrombocytopenia. Risk factors for haemorrhage include IM inj, trauma, recent surgery, women >60 yr, malignancy, PUD, potential bleeding sites & acquired or congenital hemostatic defects. Contains benzyl alcohol. Avoid use in childn <2 yr & not to be used in neonates.

Bleeding, blood clots, heparin induced thrombocytopenia, allergic reaction.

Co-administration w/ dicumarol or warfarin Na. Risk of bleeding w/ salicylic acid; dextran, phenylbutazone; indomethacin; dipyridamole; hydroxychloroquine & other drugs related to platelet aggregation reaction eg, digitalis, tetracycline, nicotine or antihistamine.

Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)

B01AB01 - heparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.

G